Stock listing
BOATS:MGNX MacroGenics, Inc. Stock
US listing (BOATS) of MacroGenics, Inc. · home listing NASDAQ:MGNX
Follow MacroGenics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:MGNX
$1.96 USD -0.01 (-0.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:MGNX
- Day range
- $1.90 – $2.08 USDNov 20, 2026
- Volume
- 1.52M sharesNov 20, 2026
- Market cap
- $125.3M USDAt the close on Nov 20, 2026 · price × 63.91M shares outstanding
- 52-week range
- $1.32 – $5.08 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.24M USDMedian day 567,617 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MGNX · Home | $1.96 USD | -0.01 (-0.5%) | 1,524,423 | $1.96 | $2.08 | $1.902 | $1.97 | Close on Nov 20, 2026 |
| Frankfurt:M55 | €1.79 EUR | 0.00 (0.0%) | — | €1.79 | €1.79 | €1.79 | €1.79 | Close on Nov 20, 2026 |
| Stuttgart:M55 | €1.79 EUR | -0.01 (-0.6%) | — | €1.78 | €1.82 | €1.73 | €1.80 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MGNX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.96 | -0.01 | -0.5% | $1.96 | $2.08 | $1.902 | 1,524,423 | |
| $1.97 | -0.08 | -3.9% | $2.02 | $2.055 | $1.935 | 720,230 | |
| $2.05 | -0.12 | -5.5% | $2.13 | $2.18 | $2.02 | 572,901 | |
| $2.17 | -0.03 | -1.4% | $2.22 | $2.25 | $1.93 | 886,956 | |
| $2.20 | -0.09 | -3.9% | $2.26 | $2.27 | $2.05 | 997,839 | |
| $2.29 | -0.03 | -1.3% | $2.31 | $2.43 | $2.24 | 894,628 | |
| $2.32 | -0.10 | -4.1% | $2.42 | $2.42 | $2.32 | 451,230 | |
| $2.42 | +0.08 | +3.4% | $2.31 | $2.43 | $2.31 | 468,034 | |
| $2.34 | +0.01 | +0.4% | $2.36 | $2.49 | $2.33 | 953,362 | |
| $2.33 | +0.11 | +5.0% | $2.26 | $2.445 | $2.25 | 695,736 | |
| $2.22 | -0.09 | -3.9% | $2.30 | $2.334 | $2.205 | 1,299,083 | |
| $2.31 | -0.02 | -0.9% | $2.39 | $2.46 | $2.23 | 918,223 | |
| $2.33 | 0.00 | 0.0% | $2.36 | $2.49 | $2.26 | 409,139 | |
| $2.33 | -0.07 | -2.9% | $2.41 | $2.535 | $2.32 | 766,095 | |
| $2.40 | +0.02 | +0.8% | $2.37 | $2.435 | $2.235 | 1,182,939 | |
| $2.38 | -0.09 | -3.6% | $2.49 | $2.59 | $2.37 | 744,074 | |
| $2.47 | +0.03 | +1.2% | $2.39 | $2.545 | $2.35 | 1,414,424 | |
| $2.44 | +0.25 | +11.4% | $2.20 | $2.56 | $2.158 | 2,120,067 | |
| $2.19 | -0.06 | -2.7% | $2.09 | $2.23 | $1.93 | 2,606,367 | |
| $2.25 | -1.38 | -38.0% | $3.55 | $3.565 | $2.13 | 4,009,664 | |
| $3.63 | +0.04 | +1.1% | $3.59 | $3.67 | $3.52 | 465,521 | |
| $3.59 | +0.10 | +2.9% | $3.45 | $3.665 | $3.45 | 398,265 | |
| $3.49 | +0.16 | +4.8% | $3.35 | $3.60 | $3.33 | 325,410 | |
| $3.33 | +0.08 | +2.5% | $3.27 | $3.435 | $3.26 | 567,617 | |
| $3.25 | -0.12 | -3.6% | $3.37 | $3.45 | $3.235 | 410,557 | |
| $3.37 | +0.06 | +1.8% | $3.34 | $3.435 | $3.30 | 578,085 | |
| $3.31 | -0.11 | -3.2% | $3.42 | $3.42 | $3.19 | 906,754 | |
| $3.42 | -0.30 | -8.1% | $3.73 | $3.73 | $3.38 | 559,140 | |
| $3.72 | -0.02 | -0.5% | $3.72 | $3.76 | $3.655 | 284,717 | |
| $3.74 | +0.19 | +5.4% | $3.53 | $3.785 | $3.52 | 418,442 | |
| $3.55 | 0.00 | 0.0% | $3.53 | $3.615 | $3.41 | 768,068 | |
| $3.55 | -0.09 | -2.5% | $3.60 | $3.73 | $3.525 | 509,978 | |
| $3.64 | -0.13 | -3.4% | $3.79 | $3.79 | $3.55 | 633,291 | |
| $3.77 | +0.19 | +5.3% | $3.65 | $3.855 | $3.495 | 605,944 | |
| $3.58 | -0.02 | -0.6% | $3.64 | $3.65 | $3.525 | 980,531 | |
| $3.60 | -0.26 | -6.7% | $3.85 | $3.88 | $3.585 | 656,628 | |
| $3.86 | +0.09 | +2.4% | $3.76 | $3.91 | $3.73 | 634,057 | |
| $3.77 | -0.29 | -7.1% | $4.08 | $4.09 | $3.75 | 616,434 | |
| $4.06 | +0.32 | +8.6% | $3.73 | $4.11 | $3.69 | 1,912,863 | |
| $3.74 | -0.06 | -1.6% | $3.79 | $3.86 | $3.72 | 604,616 | |
| $3.80 | 0.00 | 0.0% | $3.80 | $3.87 | $3.62 | 571,447 | |
| $3.80 | -0.32 | -7.8% | $4.12 | $4.12 | $3.78 | 524,592 | |
| $4.12 | 0.00 | 0.0% | $4.17 | $4.20 | $4.075 | 377,359 | |
| $4.12 | -0.02 | -0.5% | $4.16 | $4.185 | $4.08 | 310,497 | |
| $4.14 | +0.01 | +0.2% | $4.12 | $4.165 | $4.09 | 873,940 | |
| $4.13 | +0.05 | +1.2% | $4.15 | $4.18 | $4.03 | 438,002 | |
| $4.08 | +0.04 | +1.0% | $4.05 | $4.10 | $3.98 | 315,679 | |
| $4.04 | -0.16 | -3.8% | $4.19 | $4.19 | $3.99 | 264,980 | |
| $4.20 | +0.20 | +5.0% | $4.00 | $4.215 | $3.99 | 431,465 | |
| $4.00 | +0.03 | +0.8% | $4.02 | $4.09 | $3.91 | 381,932 | |
| $3.97 | -0.14 | -3.4% | $4.08 | $4.115 | $3.90 | 434,784 | |
| $4.11 | -0.21 | -4.9% | $4.29 | $4.295 | $4.03 | 599,225 | |
| $4.32 | -0.08 | -1.8% | $4.29 | $4.43 | $4.11 | 419,588 | |
| $4.40 | +0.15 | +3.5% | $4.20 | $4.49 | $4.175 | 442,785 | |
| $4.25 | -0.07 | -1.6% | $4.29 | $4.32 | $4.145 | 478,599 | |
| $4.32 | +0.28 | +6.9% | $4.05 | $4.37 | $4.045 | 581,703 | |
| $4.04 | +0.05 | +1.3% | $3.98 | $4.095 | $3.89 | 499,894 | |
| $3.99 | -0.14 | -3.4% | $4.12 | $4.13 | $3.92 | 542,802 | |
| $4.13 | +0.05 | +1.2% | $4.06 | $4.15 | $3.975 | 541,659 | |
| $4.08 | +0.04 | +1.0% | $4.05 | $4.16 | $4.05 | 319,942 | |
| $4.04 | -0.13 | -3.1% | $4.16 | $4.16 | $4.04 | 263,034 | |
| $4.17 | +0.15 | +3.7% | $4.04 | $4.195 | $4.04 | 363,137 | |
| $4.02 | -0.08 | -2.0% | $4.07 | $4.08 | $3.965 | 432,774 | |
| $4.10 | +0.03 | +0.7% | $4.09 | $4.195 | $4.035 | 271,520 | |
| $4.07 | -0.10 | -2.4% | $4.14 | $4.19 | $4.018 | 381,824 |
- Ticker
- BOATS:MGNX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Latest deck · Nov 13, 2026
Corporate Update (November 2026)
Corporate update · 28 slides
Latest news
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Nov 12, 2026
Closed $2.20 (-3.9%) on Nov 13, 2026
MacroGenics to Participate in Upcoming Investor Conferences
Nov 5, 2026
Closed $2.33 (+5.0%) on Nov 6, 2026
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
Nov 3, 2026
Closed $2.31 (-0.9%) on Nov 4, 2026
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
Oct 26, 2026
Closed $2.19 (-2.7%) on Oct 26, 2026
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
Oct 23, 2026
Closed $2.25 (-38.0%) on Oct 23, 2026
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
Oct 15, 2026
Closed $3.25 (-3.6%) on Oct 16, 2026
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026
Closed $3.97 (-3.4%) on Sep 10, 2026
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
Aug 13, 2026
Closed $4.22 (+3.4%) on Aug 14, 2026
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
Aug 11, 2026
Closed $4.02 (+2.6%) on Aug 12, 2026
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Jul 23, 2026
Closed $3.70 (-7.7%) on Jul 24, 2026
MacroGenics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 133 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 16 calls with a replay · 16 with a transcript · latest Mar 20, 2025
- Decks
- 9 decks · latest Nov 13, 2026
Where MacroGenics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MGNX · Home listing | NASDAQ | United States | USD |
| gettex:M55 | gettex | Germany | EUR |
| BOATS:MGNX · This page | BOATS | United States | USD |
| LS Exchange:A1W6ND | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1W6ND | Lang & Schwarz | Germany | EUR |
| Tradegate:M55 | Tradegate | Germany | EUR |
| BX Swiss:M55 | BX Swiss | Switzerland | CHF |
| Dusseldorf:M55 | Dusseldorf | Germany | EUR |
| Frankfurt:M55 | Frankfurt | Germany | EUR |
| Hamburg:M55 | Hamburg | Germany | EUR |
| Stuttgart:M55 | Stuttgart | Germany | EUR |
Valuation
EV/sales −0.9× against a median of 40.1×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$127.6M USD
- P/E
- Loss
- EV/sales
- −0.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.0×
- Gross margin
- 3.2%
- Operating margin
- −43.7%
- Net margin
- −34.6%
- Debt to equity
- 1.4×
- Beta vs S&P 500
- 0.83
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| Sionna Therapeutics, Inc. · NASDAQ:SION | US$127.8M | −US$89.05M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.51 |
| Yoda Pharmaceuticals Inc. · TPEX:7829 | US$127.1M | US$94.37M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| IntoCell, Inc. · KRX:287840 | US$126.6M | US$108.8M | n/a | 45.9× | n/a | 8.7× | −295.9% | 0.0× | n/a |
| UnicoCell Biomed Co., Ltd. · TWSE:6794 | US$126.3M | US$106.5M | n/a | 117× | n/a | 5.1× | −381.5% | 0.1× | n/a |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$122.6M | US$136.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.23M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| Median of the others | US$124.1M | US$95.19M | 18.4× | 40.1× | 12.3× | 3.2× | −255.4% | 0.1× | 1.37 |
Forecasts
2 strong buy · 1 buy · 4 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.47 · 1 analyst
- Revenue, year to Dec 2026
- 91.27M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jim Karrels | Senior Vice President, CFO |
Board
| Director | Role |
|---|---|
| Meenu Chhabra Karson | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| MacroGenics (NASDAQ:MGNX) Q4 2024 Earnings Call | Thu, Mar 20, 2025 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q3 2024 Earnings Call | Tue, Nov 05, 2024 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q1 2024 Earnings Call | Thu, May 09, 2024 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q4 2023 Earnings Call | Thu, Mar 07, 2024 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q3 2023 Earnings Call | Mon, Nov 06, 2023 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q2 2023 Earnings Call | Wed, Aug 09, 2023 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q1 2023 Earnings Call | Tue, May 09, 2023 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q4 2022 Earnings Call | Wed, Mar 15, 2023 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q3 2022 Earnings Call | Thu, Nov 03, 2022 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 4:30 PM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| MacroGenics (NASDAQ:MGNX) Q1 2022 Earnings Call | Tue, May 03, 2022 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q4 2021 Earnings Call | Thu, Feb 24, 2022 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q3 2021 Earnings Call | Tue, Nov 02, 2021 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q2 2021 Earnings Call | Thu, Jul 29, 2021 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q1 2021 Earnings Call | Thu, Apr 29, 2021 · 4:30 PM ET | Replay |
| MacroGenics (NASDAQ:MGNX) Q3 2020 Earnings Call | Wed, Nov 04, 2020 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −3.9% |
| Q2 2026 | Aug 13, 2026 · After close | +3.4% |
| Q1 2026 | May 13, 2026 · After close | +20.6% |
| Q4 2025 | Feb 19, 2026 | 0.0% |
| Q3 2025 | Nov 12, 2025 · After close | +8.8% |
| Q2 2025 | Aug 14, 2025 · After close | −2.5% |
| Q1 2025 | May 13, 2025 · After close | +0.7% |
| Q4 2024 | Mar 5, 2025 · Before open | +2.6% |
| Q3 2024 | Nov 5, 2024 · After close | +11.1% |
| Q2 2024 | Aug 6, 2024 · After close | −7.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −77.4% |
| Q4 2023 | Mar 7, 2024 · After close | −15.0% |
| Q3 2023 | Nov 6, 2023 · After close | +17.1% |
| Q2 2023 | Aug 9, 2023 · After close | +24.3% |
| Q1 2023 | May 9, 2023 · After close | +0.4% |
| Q4 2022 | Mar 15, 2023 · After close | +10.3% |
| Q3 2022 | Nov 3, 2022 · After close | +22.3% |
| Q2 2022 | Aug 8, 2022 · After close | +12.1% |
| Q1 2022 | May 3, 2022 · After close | −16.9% |
| Q4 2021 | Feb 24, 2022 · After close | −7.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 28 slides | Nov 13, 2026 |
| Technical Presentation (October 2026) | Technical | 24 slides | Oct 23, 2026 |
| Investor Presentation (August 2026) | Investor deck | 21 slides | Aug 13, 2026 |
| Post-ESMO Conference Call (September 2024) | Conference | 23 slides | Sep 16, 2024 |
| Technical Presentation (May 2024) | Technical | 17 slides | May 9, 2024 |
| Technical Presentation (June 2021) | Technical | 36 slides | Jun 4, 2021 |
| Investor Presentation (December 2020) | Investor deck | 14 slides | Dec 17, 2020 |
| ASCO 2020 | Conference | 18 slides | May 29, 2020 |
| ESMO 2020 | Conference | 13 slides | 2020 |
IPO
Final prospectus filed on Oct 11, 2013.
- Shares offered
- 5,000,000 shares of common stock
- Underwriters' option
- Up to 750,000 more shares
- Underwriters
- BofA Merrill Lynch, Leerink Swann, Stifel, Lazard Capital Markets, Wedbush PacGrow Life Sciences · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 2, 2013 |
| Filed publicly | Sep 4, 2013 |
| Amended 4 times | Newest Oct 9, 2013 |
| Shares registered with an exchange | Oct 7, 2013 |
| Declared effective by the SEC | Oct 9, 2013 |
| Final prospectus, with the price | Oct 11, 2013 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 11, 2013 |
| EFFECT · Notice that a registration is effective | Oct 9, 2013 |
| S-1/A · Registration statement, amended | Oct 9, 2013 |
| CERTNAS · Nasdaq's certificate of listing | Oct 8, 2013 |
| UPLOAD · Letter from the SEC | Oct 7, 2013 |
| CORRESP · Letter to the SEC | Oct 7, 2013 |
| CORRESP · Letter to the SEC | Oct 7, 2013 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 7, 2013 |
| S-1/A · Registration statement, amended | Oct 4, 2013 |
| UPLOAD · Letter from the SEC | Oct 3, 2013 |
All 21 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Oct 1, 2013 |
| CORRESP · Letter to the SEC | Oct 1, 2013 |
| CORRESP · Letter to the SEC | Sep 27, 2013 |
| CORRESP · Letter to the SEC | Sep 26, 2013 |
| CORRESP · Letter to the SEC | Sep 26, 2013 |
| UPLOAD · Letter from the SEC | Sep 26, 2013 |
| S-1/A · Registration statement, amended | Sep 20, 2013 |
| UPLOAD · Letter from the SEC | Sep 18, 2013 |
| S-1 · Registration statement | Sep 4, 2013 |
| UPLOAD · Letter from the SEC | Aug 28, 2013 |
| DRS · Draft registration statement | Aug 2, 2013 |
Open IPO · From the cover of the amended prospectus (S-1/A) filed Oct 9, 2013
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 149.5M | 150.0M | 58.7M | 151.9M | 77.4M | 104.9M | 64.2M | 60.1M | 157.7M | 91.9M |
| Cost of revenue | 0 | 847.0K | 619.0K | 3.35M | 2.65M | 0 | 0 | 190.8M | 147.2M | 122.1M |
| Gross profit | 106.3M | 136.0M | 49.0M | 144.6M | 73.0M | 97.8M | 62.0M | 60.1M | 155.5M | 86.6M |
| Research and development | 147.2M | 177.2M | 166.6M | 207.0M | 214.6M | 193.2M | 195.3M | 190.8M | 147.2M | 122.1M |
| Selling, general and administrative | 39.2M | 71.0M | 52.2M | 58.9M | 63.0M | 42.7M | 46.1M | 40.5M | 32.7M | 29.8M |
| Operating income | -72.8M | -110.6M | -168.2M | -121.4M | -202.8M | -131.1M | -177.2M | -171.2M | -22.1M | -60.0M |
| Depreciation and amortization | 7.17M | 7.54M | 9.64M | 11.9M | 11.3M | 12.0M | 12.3M | 9.16M | 7.23M | 7.61M |
| EBITDA | -65.7M | -103.0M | -158.6M | -109.6M | -191.5M | -119.1M | -164.9M | -162.0M | -14.9M | -52.4M |
| Interest expense | 8.51M | 1.11M | 1.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | -75.3M | -66.0M | -9.06M | -119.8M | -202.1M | -129.7M | -151.8M | -171.5M | -19.6M | -58.5M |
| Income tax | -672.0K | 944.0K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -74.6M | -67.0M | -9.06M | -119.8M | -202.1M | -129.7M | -151.8M | -171.5M | -19.6M | -58.5M |
| Earnings per share, basic | -1.18 | -1.07 | -0.15 | -1.95 | -3.37 | -2.47 | -3.10 | -4.05 | -0.54 | -1.69 |
| Earnings per share, diluted | -1.18 | -1.07 | -0.15 | -1.95 | -3.37 | -2.47 | -0.54 | -1.69 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 57.2M | 182.8M | 101.0M | 108.9M | 123.5M | 181.1M | 126.5M | 220.1M | 211.7M | 84.1M |
| Short-term investments | 132.7M | 18.8M | 128.8M | 45.5M | 120.1M | 91.4M | 89.3M | 12.7M | 93.4M | 192.9M |
| Receivables | 427.0K | 4.31M | 10.4M | 56.2M | 10.4M | 23.1M | 12.7M | 29.6M | 13.6M | 2.76M |
| Inventory | 7.91M | 0 | 1.22M | 1.45M | 4.39M | 0 | 1 | 0 | -7.99M | |
| Current assets | 219.9M | 217.5M | 251.3M | 222.2M | 279.6M | 312.6M | 239.8M | 269.1M | 322.3M | 283.9M |
| Property, plant and equipment | 2.10M | 18.1M | 21.8M | 29.6M | 37.7M | 42.2M | 48.2M | 56.7M | 50.0M | 18.0M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 256.8M | 261.7M | 298.4M | 280.5M | 335.2M | 378.7M | 312.5M | 332.1M | 373.9M | 311.3M |
| Accounts payable | 3.26M | 5.01M | 6.44M | 4.90M | 15.5M | 8.03M | 4.31M | 4.00M | 2.45M | 4.00M |
| Current liabilities | 43.1M | 55.5M | 56.1M | 48.6M | 74.6M | 50.7M | 45.2M | 59.9M | 49.8M | 27.3M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 106.8M | 37.5M | 34.0M | 34.8M | 25.5M | 29.2M | 30.6M | 298.0K | 1.89M | |
| Total liabilities | 201.3M | 145.6M | 145.8M | 138.5M | 95.6M | 82.9M | 81.9M | 89.3M | 74.6M | 42.5M |
| Shareholders' equity | 55.6M | 116.1M | 152.6M | 142.0M | 239.6M | 295.9M | 230.6M | 242.9M | 299.2M | 268.8M |
| Shares outstanding | 63.3M | 62.8M | 62.1M | 61.7M | 61.3M | 56.2M | 49.0M | 42.4M | 36.9M | 34.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -81.0M | -68.4M | -78.2M | -87.0M | -143.8M | -111.9M | -134.3M | -153.2M | 14.4M | -43.7M |
| Capital spending | -1.91M | -3.71M | -1.76M | -3.62M | -6.20M | -5.91M | -4.29M | -25.0M | -29.4M | -11.4M |
| Free cash flow | -83.0M | -72.1M | -80.0M | -90.6M | -150.0M | -117.8M | -138.6M | -178.2M | -15.0M | -55.1M |
| Cash from investing | -114.1M | 149.3M | -80.1M | 70.7M | -36.6M | -7.79M | -79.4M | 56.6M | 77.9M | -70.2M |
| Cash from financing | 69.5M | 960.0K | 150.4M | 1.66M | 122.8M | 174.3M | 120.0M | 105.0M | 35.3M | 1.85M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | -306.0K | 1.08M | 117.8M | -2.01M | 0 | -260.0K | -40.0K | -39.0K | ||
| Change in cash | -125.6M | 81.9M | -7.93M | -14.6M | -57.7M | 54.7M | -93.7M | 8.40M | 127.6M | -112.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Oct 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Sep 3, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Sep 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 20, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 13, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 8, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 7, 2026 | Acquisition or disposal | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 8-K · Current report | May 20, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Material contract | SEC |
| 8-K · Current report | May 4, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 8, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 13, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 10, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 8-K · Current report | May 22, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 11, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 13, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jan 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 3, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 21, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Nov 20, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 16, 2024 | Current report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| 8-K · Current report | Jul 30, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jun 4, 2024 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2024 | Insider trade | SEC |
| 8-K · Current report | May 23, 2024 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | May 23, 2024 | Offer document | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | May 21, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 8, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 8, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 4, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 7, 2024 | Results | SEC |
| 10-K · Annual report | Mar 7, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 26, 2024 | Other filings | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
This page holds 200 of 948 filings. Open Filings
Cap table
Built by 6ix from MacroGenics, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 63,908,946
- Fully diluted
- 63,908,946
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 63,908,946 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 63,908,946 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Arnold L Oronsky Other companies: PMV Pharmaceuticals, Inc. (Director · Sep 24, 2020 – Sep 25, 2020 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 1, 2020 · Past); Tesaro Inc (Director · Jun 27, 2012 – Aug 7, 2018 · Past); Anesiva Inc (Director · Jun 22, 2006 – May 9, 2008 · Past); Myogen Inc (Director · May 4, 2006 – Nov 13, 2006 · Past); Dynavax Technologies Corporation (Director · Feb 23, 2006 – May 28, 2020 · Past) | Director · Oct 9, 2013 – Feb 18, 2014 · Past |
| David Stump Other companies: Regenxbio Inc. (Independent Board Member · Since at least Oct 14, 2015); Portola Pharmaceuticals Inc (Director · Sep 24, 2015 – Jul 2, 2020 · Past); Dendreon Corp (Director · Jun 2, 2010 – Jan 3, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Jun 18, 2009 – Jun 30, 2020 · Past); Human Genome Sciences Inc (Exec. Vice President · Mar 10, 2009 – Jul 30, 2012 · Past) | Director · Since at least Oct 9, 2013 |
| Edward Hurwitz Other companies: Dyne Therapeutics, Inc. (Director · Since at least Jul 31, 2020); Turmeric Acquisition Corp (Chief Financial Officer · Oct 15, 2020 – Oct 15, 2020 · Past); Tvardi Therapeutics, Inc. (Director · Jan 30, 2014 – Feb 5, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Apr 3, 2009 – Jun 28, 2013 · Past) | Director · Since at least Oct 9, 2013 |
| Scott Thomas Jackson Other companies: Mural Oncology plc (Director · Since at least Oct 31, 2023); Spero Therapeutics, Inc. (Director · Since at least Apr 16, 2020); Crescent Biopharma, Inc. (Director · Nov 27, 2018 – May 1, 2024 · Past); Celator Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 14, 2013 – Jul 12, 2016 · Past) | Director · Since at least Jan 24, 2017 |
| Eran Nadav Other companies: Trevi Therapeutics, Inc. (Director · May 7, 2019 – May 7, 2019 · Past); Collegium Pharmaceutical, Inc. (Director · May 6, 2015 – Jun 9, 2016 · Past); Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Jul 10, 2014 · Past) | Director · Oct 9, 2013 – Oct 9, 2013 · Past |
| Jon Marc Wigginton Other companies: Sutro Biopharma, Inc. (Director · Since at least Nov 30, 2020); Checkmate Pharmaceuticals Inc (Director · Jan 30, 2022 – May 31, 2022 · Past); Cullinan Therapeutics, Inc. (Chief Medical Officer · Jan 7, 2021 – Jan 7, 2021 · Past) | Sr VP, Clinical Dev. & CMO · Oct 9, 2013 – Feb 20, 2020 · Past |
| Kenneth Galbraith Other companies: Theravance Biopharma, Inc. (Chair & CEO · Since at least Nov 5, 2026); Zymeworks Inc. (Chair & CEO · Since at least Jan 15, 2022); Celator Pharmaceuticals Inc (Director · Jan 14, 2013 – Jun 3, 2013 · Past) | Director · Oct 9, 2013 – May 13, 2021 · Past |
| Meenu Chhabra Other companies: Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past); GRI Bio, Inc. (Director · Feb 23, 2022 – Feb 23, 2022 · Past); Kineta Inc. (President and CEO, Director · Feb 10, 2016 – Mar 2, 2020 · Past) | Director · Since at least Jan 3, 2023 |
| Atul Saran Other companies: Emergent BioSolutions Inc. (EVP, Chief Strat & Dev Officer · Jul 20, 2017 – Feb 28, 2023 · Past); Xencor, Inc. (Director · Dec 2, 2013 – Dec 6, 2013 · Past) | SVP & General Counsel · Jun 5, 2014 – Apr 28, 2017 · Past |
| Paulo F Costa Other companies: CorMedix Inc. (Director · Sep 15, 2020 – May 17, 2023 · Past); Amylin Pharmaceuticals LLC (Director · Jun 9, 2009 – Aug 8, 2012 · Past) | Director · Oct 9, 2013 – May 13, 2021 · Past |
All 26 people
| Person | Seat |
|---|---|
| Federica F O'Brien Other companies: TELA Bio, Inc. (Director · Since at least Nov 7, 2019) | Director · Since at least Feb 10, 2021 |
| Karen Ferrante Other companies: Cogent Biosciences, Inc. (Director · Since at least Oct 1, 2020) | Director · Since at least May 13, 2021 |
| Scott Koenig Other companies: Crescent Biopharma, Inc. (Director · Mar 9, 2017 – May 1, 2024 · Past) | Director · Since at least Oct 9, 2013 |
| William Heiden Other companies: Atara Biotherapeutics, Inc. (Director · Since at least Jun 23, 2022) | Director · Since at least May 23, 2022 |
| Beth Ann Smith | VP, Controller & Treasurer · Since at least Jan 2, 2025 |
| Eric Risser | President and CEO, Director · Since at least Oct 9, 2013 |
| Ezio Bonvini | Sr VP, Research & CSO · Since at least Feb 20, 2020 |
| James Karrels | SVP and CFO · Since at least Jun 15, 2022 |
| Jay Philip Siegel | Director · Since at least Nov 13, 2017 |
| Jeffrey Stuart Peters | Senior VP, GC, and Secretary · Since at least Dec 31, 2017 |
| Jim Karrels | Senior Vice President, CFO · Since at least Nov 3, 2026 |
| Lynn Cilinski | VP, Controller and Treasurer · Oct 9, 2013 – Feb 15, 2024 · Past |
| Margaret Liu | Director · Since at least Jan 3, 2023 |
| Meenu Chhabra Karson | Director · Since at least Nov 5, 2026 |
| Stephen L Eck | Chief Medical Officer · Feb 15, 2023 – Feb 15, 2025 · Past |
| Thomas Spitznagel | Sr VP, Technical Ops · Since at least Feb 8, 2024 |
Log in to ask 6ix AI your own questions about MacroGenics, Inc.